Metabolic Syndrome in Saudi Arabia: Prevalence, Diagnosis and Care

From a public health perspective in Saudi Arabia and the Gulf region, MetS is a priority because the region records some of the world’s highest rates of obesity and diabetes—key drivers of the syndrome. Lifestyle interventions (weight reduction, increased dietary fibre, structured physical activity, sleep and stress management, and time‑restricted eating in selected contexts) are foundational and often yield clinically meaningful improvements across multiple MetS components. Nutritional strategies that increase soluble and insoluble dietary fibre are supported by systematic reviews and meta-analyses that link higher fibre intake to lower incidence and severity of MetS components. Complementary products—such as yerba mate extracts (commercially formulated in products like Unimate) and fibre supplements—have been used as adjuncts within structured programs (e.g., the Feel Great system), but clinical evidence varies and such products should be integrated cautiously and not replace standard medical care. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5793252/?utm_source=openai))

2. Prevalence and burden in Saudi Arabia and the Gulf

Published population studies and national datasets indicate high prevalence of MetS in Saudi Arabia, with estimates typically ranging from approximately 31% to nearly 40% depending on the diagnostic criteria (IDF versus ATP III) and waist circumference thresholds applied. A population-based cross‑sectional study and subsequent analyses have reported prevalence figures in these ranges in adult Saudis, reflecting the combined effects of obesity, dysglycaemia and dyslipidaemia. Across the Gulf Cooperation Council (GCC), a meta-analysis summarizing cross-sectional studies reported similarly elevated and variable prevalence among member states, again influenced by heterogeneity in definitions and sample selection. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5838993/?utm_source=openai))

Related disease burden is evident: international sources (WHO and IDF) show high adult diabetes prevalence in Saudi Arabia (estimates commonly cited in national and IDF reports fall between ~18% and >20% in adults in some reports) and obesity prevalence estimates often exceed 35% in adults by WHO age‑standardized metrics. The co-occurrence of obesity and diabetes accelerates population-level cardiometabolic disease burden and health-care resource use, including hospitalizations for acute coronary syndromes and long-term management of diabetic complications. Global burden analyses (e.g., GBD and Lancet publications) underscore the increasing impact of metabolic risks including raised BMI and glucose on national disease profiles. ([diabetesatlas.org](https://www.diabetesatlas.org/data/upload/download/mena_factsheet_en.pdf?utm_source=openai))

3. Local risk factors: lifestyle, diet, and genetics

Risk factors for MetS in Saudi Arabia mirror global drivers but have regional amplifiers. Rapid urbanization, dietary shifts toward energy-dense processed foods and sugar‑sweetened beverages, decreased occupational and leisure activity, and sedentary behaviours contribute substantially. National studies (e.g., SAUDI‑DM and other population surveys) link increased BMI and central obesity to rising prevalence of insulin resistance and MetS components. Smoking, poor sleep, psychosocial stress, and perinatal factors (including gestational diabetes) also increase lifetime risk. Furthermore, population‑specific anthropometry means that applying localized waist circumference cut‑offs improves detection: Saudi data have suggested cut‑points different from European standards to better predict metabolic risk. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7999834/?utm_source=openai))

Genetic predisposition interacts with the obesogenic environment in the Gulf—polymorphisms affecting fat distribution, adipocyte biology, and insulin sensitivity may modulate individual susceptibility. Consequently, prevention strategies must combine population-level policy (taxation of sugary drinks, labeling, urban planning to encourage activity) with personalized clinical approaches that address behaviour change. Dietary fibre intake is a scalable intervention with robust evidence supporting reductions in inflammatory markers and improvements in insulin sensitivity, making it a practical cornerstone of local prevention efforts. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5793252/?utm_source=openai))

4. Diagnostic criteria and early screening in Saudi practice

Clinically, the harmonized diagnostic framework for MetS requires the presence of three or more of five components: abdominal obesity (waist circumference above population‑specific threshold), fasting glucose ≥100 mg/dL (or treatment for hyperglycaemia), triglycerides ≥150 mg/dL, HDL cholesterol <40 mg/dL in men or <50 mg/dL in women, and blood pressure ≥130/85 mmHg (or antihypertensive treatment). Saudi studies emphasize using population‑adapted waist circumference values (some research suggests cut‑offs around ≥92 cm in men and ≥87 cm in women for Saudi adults in certain cohorts) for improved diagnostic accuracy. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/16182882/?from_term=The+metabolic+syndrome+%E2%80%93+a+new+worldwide+definition.+&utm_source=openai))

Screening strategy in primary care should prioritize adults over 30 years or any adult with risk factors (obesity, family history of T2DM, previous gestational diabetes). Practical screening includes waist measurement, blood pressure, fasting plasma glucose or HbA1c, and fasting lipid panel. Frequency of re‑screening is individualized (commonly every 1–3 years depending on risk). In Saudi Arabia, integrating structured screening within primary care and national NCD programs improves early identification and linkage to lifestyle interventions or specialty care. Electronic health records and standardized referral pathways help ensure at‑risk patients receive timely dietetic and exercise counselling. ([who.int](https://www.who.int/teams/noncommunicable-diseases/surveillance/data/saudi-arabia?utm_source=openai))

5. Complications and cardiometabolic risk management

MetS increases risk for major adverse cardiovascular events, progression to T2DM, chronic kidney disease, and NAFLD. Therefore management aims to reduce these risks by treating individual components and the syndrome as a whole. Evidence-based priorities include sustained weight loss (5–10% weight reduction often yields meaningful metabolic improvements), dietary modification (reduced refined carbohydrate and saturated fat intake, increased dietary fibre), regular aerobic and resistance exercise (targeting ≥150 min/week of moderate exercise), smoking cessation, and optimized blood pressure and lipid management (e.g., statins for dyslipidaemia when indicated). Newer glucose-lowering agents with cardiovascular benefit (e.g., SGLT2 inhibitors, GLP‑1 receptor agonists) may be used when glycaemic control requires pharmacotherapy and when cardiovascular or renal risk justifies their use. ([doi.org](https://doi.org/10.1016/S0140-6736%2823%2901301-6?utm_source=openai))

Adjunctive approaches—nutraceuticals and functional foods—are frequently considered. Dietary fibre supplements have consistent evidence for glycaemic and lipid improvements. Trials of yerba mate (Ilex paraguariensis) show heterogeneous but sometimes promising effects on weight, lipids and glucose; recent randomized crossover trials and systematic reviews have suggested modest cardiometabolic benefits in at‑risk participants, though results vary by dose, preparation, and study design. Commercial products such as Unimate are formulated yerba mate extracts used in programs like Feel Great; some company‑sponsored data and clinical trial registrations exist, but independent corroboration and long‑term outcome data remain limited—these products are best used as adjuncts within comprehensive lifestyle programs and under clinical supervision. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5793252/?utm_source=openai))

6. Prevention and treatment: lifestyle programs, medical interventions, follow‑up plans

Comprehensive prevention and treatment programs for MetS must be multimodal. Primary prevention at population level includes fiscal measures (taxes on sugar‑sweetened beverages), food reformulation, front‑of‑pack labeling, school and workplace wellness programs, and urban designs that promote physical activity—measures that have been recommended by WHO and regional policy documents. Clinically, individualized care pathways should include structured weight management programs with dietary counselling emphasizing high‑fibre, minimally processed diets; behaviour‑change support; and supervised exercise prescriptions. Evidence shows increased dietary fibre reduces MetS incidence and improves metabolic biomarkers; thus fibre augmentation—through whole foods or targeted supplements—should be a standard component of therapeutic plans when intake is insufficient. ([who.int](https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases?utm_source=openai))

For patients requiring medication, treat-to-target strategies for blood pressure, lipids and glucose are necessary. Follow-up should include periodic monitoring of weight, waist circumference, BP, fasting lipids, and glycaemic markers (fasting glucose/HbA1c) every 3–12 months depending on control. Digital health tools, remote coaching, and multidisciplinary teams (physicians, dietitians, physiotherapists, behavioural specialists) improve adherence and outcomes. Programs such as the Feel Great system combine intermittent fasting patterns with a pre‑meal fibre product and morning yerba mate (Unimate), aiming to support appetite control and adherence; randomized trials on combined interventions are limited but ongoing, so clinicians should monitor outcomes and adverse effects when supporting such approaches. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05493553?utm_source=openai))

7. Policy recommendations and local resources for patients and providers

Actionable recommendations for Saudi health systems and policymakers include: implementing nationwide screening and registry for MetS components; adopting population‑specific waist circumference cut‑offs in clinical guidelines; strengthening primary care capacity for lifestyle counselling; enforcing policies that reduce dietary risks (e.g., SSB taxes, labeling); expanding access to community physical activity options (including safe spaces for women); and funding implementation research adapted to local culture. WHO and regional policy briefs provide frameworks for such multi-sectoral strategies. ([applications.emro.who.int](https://applications.emro.who.int/docs/KSA-NCD-IC-v15-eng.pdf?utm_source=openai))

For patients, practical steps are: measure and track weight and waist circumference, adopt a fibre-rich dietary pattern (aim ≥25–30 g/day), increase daily physical activity incrementally toward 150 minutes/week of moderate exercise, stop smoking, and attend regular follow-up visits. If considering adjunctive supplements (fibre blends, yerba mate products like Unimate within a program such as Feel Great), do so in consultation with a clinician—these may aid satiety and metabolic markers in some trials but should not replace standard therapies where medications are indicated. The evidence for dietary fibre is robust and should be prioritized; evidence for yerba mate shows potential but remains heterogeneous, and product‑specific claims (including those by manufacturers) require careful evaluation and clinical judgment. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5793252/?utm_source=openai))

Summary table — selected statistics (KSA & GCC)

Key takeaways: Metabolic syndrome is common and clinically important in Saudi Arabia and the Gulf. Priorities are early detection, population and clinical interventions to reduce obesity and diabetes, and evidence‑based lifestyle programs that emphasize increased dietary fibre and structured activity. Adjunctive products—such as targeted fibre supplements and yerba mate formulations (used in programs like Feel Great with Unimate)—may support adherence and some biomarkers but should be integrated as supportive elements under clinical oversight.

Selected references: peer‑reviewed studies and reviews from PubMed/PMC on MetS prevalence in KSA, GCC meta-analyses, WHO NCD reports, IDF Diabetes Atlas, Nature Reviews Endocrinology and Lancet/GBD analyses on metabolic risk and burden, RCTs and systematic reviews of dietary fibre, and clinical trials/reports on Ilex paraguariensis (yerba mate) and product registries (including clinical trial NCT05493553 and manufacturer materials for Unimate). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5838993/?utm_source=openai))